Please use this identifier to cite or link to this item:
|Title:||Is there a link between bisphenol A (BPA), a key endocrine disruptor, and the risk for SARS-CoV-2 infection and severe COVID-19?|
De Aguiar Greca, S-C
|Keywords:||SARS-CoV-2;COVID-19;BPA;estrogen receptors;ACE2;TMPRSS2;endocrine disruptors|
|Citation:||Journal of Clinical Medicine, in press|
|Abstract:||© 2020 by the authors. Infection by the severe acute respiratory syndrome (SARS) coronavirus-2 (SARS-CoV-2) is the causative agent of a new disease (COVID-19). The risk of severe COVID-19 is increased by certain underlying comorbidities, including asthma, cancer, cardiovascular disease, hypertension, diabetes, and obesity. Notably, exposure to hormonally active chemicals, so called, endocrine disrupting chemicals (EDCs) can promote such cardio-metabolic diseases, endocrine-related cancers, and immune system dysregulation and, thus, may also be linked to higher risk of severe COVID-19. Bisphenol A (BPA) is among the most common EDCs and exerts its effects via receptors which are widely distributed in human tissues, including nuclear estrogen receptors (ERα and ERβ), membrane-bound estrogen receptor GPR30 and human nuclear receptor estrogen-related receptor gamma. As such, this paper focuses on the potential role of BPA in promoting comorbidities associated with severe COVID-19, as well as on potential BPA-induced effects on key SARS-CoV-2 infection mediators, such as angiotensin-converting enzyme 2 (ACE2), and transmembrane serine protease 2 (TMPRSS2). Interestingly, GPR30 appears to exhibit greater co-localisation with TMPRSS2 in key tissues like lung, and prostate, suggesting that BPA exposure may impact on the local expression of these SARS-CoV-2 infection mediators. Overall, the potential role of BPA on the risk and severity of COVID-19 merits further investigation.|
|Appears in Collections:||Dept of Life Sciences Research Papers|
Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.